Drug Fights Osteoporosis, Heart Disease, Without Cancer Risk

A 1996 study of 400 menopausal women found that the drug raloxifene, sold under the brand name Evista, lowered women’s “bad” cholesterol and increased their levels of “good cholesterol.”

Raloxifene, though not as effective estrogen in maintaining good cholesterol levels, may be preferable to estrogen and other estrogen-like drugs because it effectively fights the problems associated with heart disease and osteoporosis without increasing a woman’s risk of breast or uterine cancer.


AP - May 13, 1998

Support eh ERA banner